Orteronel for the treatment of prostate cancer

Kathryn Van Hook, Ted Huang, Joshi Alumkal

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    Orteronel (also known as TAK-700) is a novel hormonal therapy that is currently in testing for the treatment of prostate cancer. Orteronel inhibits the 17,20 lyase activity of the enzyme CYP17A1, which is important for androgen synthesis in the testes, adrenal glands and prostate cancer cells. Preclinical studies demonstrate that orteronel treatment suppresses androgen levels and causes shrinkage of androgen-dependent organs, such as the prostate gland. Early reports of clinical studies demonstrate that orteronel treatment leads to reduced prostate-specific antigen levels, a marker of prostate cancer tumor burden, and more complete suppression of androgen synthesis than conventional androgen deprivation therapies that act in the testes alone. Treatment with single-agent orteronel has been well tolerated with fatigue as the most common adverse event, while febrile neutropenia was the dose-limiting toxicity in a combination study of orteronel with docetaxel. Recently, the ELM-PC5 Phase III clinical trial in patients with advanced-stage prostate cancer who had received prior docetaxel was unblinded as the overall survival primary end point was not achieved. However, additional Phase III orteronel trials are ongoing in men with earlier stages of prostate cancer.

    Original languageEnglish (US)
    Pages (from-to)803-811
    Number of pages9
    JournalFuture Oncology
    Volume10
    Issue number5
    DOIs
    StatePublished - 2014

    Fingerprint

    Prostatic Neoplasms
    Androgens
    docetaxel
    Therapeutics
    Testis
    Adrenal Gland Neoplasms
    Steroid 17-alpha-Hydroxylase
    Febrile Neutropenia
    Phase III Clinical Trials
    orteronel
    Prostate-Specific Antigen
    Tumor Burden
    Fatigue
    Prostate
    Survival
    Enzymes

    Keywords

    • 17,20 lyase
    • CYP17A1
    • orteronel
    • prostate cancer
    • TAK-700

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research
    • Medicine(all)

    Cite this

    Orteronel for the treatment of prostate cancer. / Van Hook, Kathryn; Huang, Ted; Alumkal, Joshi.

    In: Future Oncology, Vol. 10, No. 5, 2014, p. 803-811.

    Research output: Contribution to journalArticle

    Van Hook, Kathryn ; Huang, Ted ; Alumkal, Joshi. / Orteronel for the treatment of prostate cancer. In: Future Oncology. 2014 ; Vol. 10, No. 5. pp. 803-811.
    @article{dd901ce3757040f8acbe2676aa7cec2a,
    title = "Orteronel for the treatment of prostate cancer",
    abstract = "Orteronel (also known as TAK-700) is a novel hormonal therapy that is currently in testing for the treatment of prostate cancer. Orteronel inhibits the 17,20 lyase activity of the enzyme CYP17A1, which is important for androgen synthesis in the testes, adrenal glands and prostate cancer cells. Preclinical studies demonstrate that orteronel treatment suppresses androgen levels and causes shrinkage of androgen-dependent organs, such as the prostate gland. Early reports of clinical studies demonstrate that orteronel treatment leads to reduced prostate-specific antigen levels, a marker of prostate cancer tumor burden, and more complete suppression of androgen synthesis than conventional androgen deprivation therapies that act in the testes alone. Treatment with single-agent orteronel has been well tolerated with fatigue as the most common adverse event, while febrile neutropenia was the dose-limiting toxicity in a combination study of orteronel with docetaxel. Recently, the ELM-PC5 Phase III clinical trial in patients with advanced-stage prostate cancer who had received prior docetaxel was unblinded as the overall survival primary end point was not achieved. However, additional Phase III orteronel trials are ongoing in men with earlier stages of prostate cancer.",
    keywords = "17,20 lyase, CYP17A1, orteronel, prostate cancer, TAK-700",
    author = "{Van Hook}, Kathryn and Ted Huang and Joshi Alumkal",
    year = "2014",
    doi = "10.2217/fon.14.35",
    language = "English (US)",
    volume = "10",
    pages = "803--811",
    journal = "Future Oncology",
    issn = "1479-6694",
    publisher = "Future Medicine Ltd.",
    number = "5",

    }

    TY - JOUR

    T1 - Orteronel for the treatment of prostate cancer

    AU - Van Hook, Kathryn

    AU - Huang, Ted

    AU - Alumkal, Joshi

    PY - 2014

    Y1 - 2014

    N2 - Orteronel (also known as TAK-700) is a novel hormonal therapy that is currently in testing for the treatment of prostate cancer. Orteronel inhibits the 17,20 lyase activity of the enzyme CYP17A1, which is important for androgen synthesis in the testes, adrenal glands and prostate cancer cells. Preclinical studies demonstrate that orteronel treatment suppresses androgen levels and causes shrinkage of androgen-dependent organs, such as the prostate gland. Early reports of clinical studies demonstrate that orteronel treatment leads to reduced prostate-specific antigen levels, a marker of prostate cancer tumor burden, and more complete suppression of androgen synthesis than conventional androgen deprivation therapies that act in the testes alone. Treatment with single-agent orteronel has been well tolerated with fatigue as the most common adverse event, while febrile neutropenia was the dose-limiting toxicity in a combination study of orteronel with docetaxel. Recently, the ELM-PC5 Phase III clinical trial in patients with advanced-stage prostate cancer who had received prior docetaxel was unblinded as the overall survival primary end point was not achieved. However, additional Phase III orteronel trials are ongoing in men with earlier stages of prostate cancer.

    AB - Orteronel (also known as TAK-700) is a novel hormonal therapy that is currently in testing for the treatment of prostate cancer. Orteronel inhibits the 17,20 lyase activity of the enzyme CYP17A1, which is important for androgen synthesis in the testes, adrenal glands and prostate cancer cells. Preclinical studies demonstrate that orteronel treatment suppresses androgen levels and causes shrinkage of androgen-dependent organs, such as the prostate gland. Early reports of clinical studies demonstrate that orteronel treatment leads to reduced prostate-specific antigen levels, a marker of prostate cancer tumor burden, and more complete suppression of androgen synthesis than conventional androgen deprivation therapies that act in the testes alone. Treatment with single-agent orteronel has been well tolerated with fatigue as the most common adverse event, while febrile neutropenia was the dose-limiting toxicity in a combination study of orteronel with docetaxel. Recently, the ELM-PC5 Phase III clinical trial in patients with advanced-stage prostate cancer who had received prior docetaxel was unblinded as the overall survival primary end point was not achieved. However, additional Phase III orteronel trials are ongoing in men with earlier stages of prostate cancer.

    KW - 17,20 lyase

    KW - CYP17A1

    KW - orteronel

    KW - prostate cancer

    KW - TAK-700

    UR - http://www.scopus.com/inward/record.url?scp=84899825395&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84899825395&partnerID=8YFLogxK

    U2 - 10.2217/fon.14.35

    DO - 10.2217/fon.14.35

    M3 - Article

    C2 - 24799061

    AN - SCOPUS:84899825395

    VL - 10

    SP - 803

    EP - 811

    JO - Future Oncology

    JF - Future Oncology

    SN - 1479-6694

    IS - 5

    ER -